https://www.thebodypro.com/category/prezista-pro

Darunavir (Prezista)

The Latest

Boosted Darunavir Is Associated With Higher Cardiovascular Risk in D:A:D Study, but Not Atazanavir Img
Cardiovascular

Boosted Darunavir Is Associated With Higher Cardiovascular Risk in D:A:D Study, but Not Atazanavir

Cumulative use of the boosted protease inhibitor darunavir/ritonavir was associated with an approximately 60% higher rate of developing heart disease over five years, in an analysis from the D:A:D study.

No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy Registry Img

No Increased Risk of Birth Defects With Darunavir: Findings From the Antiretroviral Pregnancy Registry

The Antiretroviral Pregnancy Registry found no apparent increase in the frequency of specific birth defects with first trimester darunavir exposure.

Updates for Prezista (Darunavir) for Use in Pregnant Women Img
News

Updates for Prezista (Darunavir) for Use in Pregnant Women

On June 17, 2016, the U.S. Food and Drug Administration approved updates to the Prezista (darunavir) labeling to include information on the use of darunavir in pregnant women.

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results Img
News

Maintenance HIV Regimen of Rilpivirine and Boosted Darunavir as Effective as Three-Drug Treatment in Early Results

Rilpivirine (Edurant) plus ritonavir-boosted darunavir (Prezista) as HIV maintenance therapy compared similarly to a three-drug regimen of a boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors, according to a study presente...

Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine Img
News

Pharmacokinetics in Pregnancy: Darunavir/Ritonavir and Etravirine

Two small studies presented at the 5th International Workshop on HIV & Women evaluated the pharmacokinetics of darunavir/ritonavir (DRV/r) and etravirine (ETV) respectively in pregnancy. In both studies drug exposure was altered -- lower for DRV and ...

Equivalent Efficacy With Lower Dose Darunavir Img

Equivalent Efficacy With Lower Dose Darunavir

A reduced dose of darunavir boosted with ritonavir was effective in two reports from Italy and Spain.

Promo Image

Dual Therapy With Raltegravir and Darunavir

The leading U.S. HIV treatment guidelines developed by the U.S. Department of Health and Human Services (DHHS) for adults have several regimens that it recommends from which doctors and their patients can choose for the initial therapy of HIV. These ...

Promo Image
Conference Coverage

Atazanavir, Raltegravir and Darunavir Virologically Equivalent in Naive Patients but Significant Differences for Tolerability: Results From ACTG 5257

Primary results from the ACTG 5257 study shifted the assumed relative parity between three of the preferred first-line combinations in US DHHS guidelines. Raphael Landovitz from University of California Los Angeles, presented results at CROI 2014 fro...

Promo Image
Lipodystrophy/Body Fat

Darunavir-Ritonavir Monotherapy: Impact on Fat and Bones

Darunavir is a powerful protease inhibitor. In a previous trial called Monet, results showed that switching to darunavir-ritonavir monotherapy from standard triple therapy (ART) is roughly as effective as ART.

The Monarch Study

In a substudy of a t...

Promo Image

Dolutegravir vs. Darunavir for the Initial Treatment of HIV

Darunavir (sold as Prezista) belongs to the class of HIV drugs called protease inhibitors. Darunavir is taken with a small dose of another protease inhibitor, ritonavir (Norvir), as ritonavir boosts darunavir levels in the blood so that once-daily do...